CTOs on the Move

Accure Acne

www.accureacne.com

 
At Accure, we are wholly committed to developing revolutionary solutions to provide a long-lasting, durable response to acne. We know that acne can have a devastating social, psychological, physical, and economic impact on patients around the world. We are pioneering transformative solutions that will answer this unmet need and have a positive and profound impact on patients and providers worldwide.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.accureacne.com
  • 4699 Nautilus Court South Suite 205
    Boulder, CO USA 80301
  • Phone: 303.886.6125

Executives

Name Title Contact Details
Alfred Intintoli
Chief Technology Officer Profile

Funding

Accure Acne raised $20M on 04/22/2021

Similar Companies

Canadian Orthotics Laboratory

Canadian Orthotics Laboratory is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VeriChip Corporation

VeriChip Corporation is a Delray Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Etex

Etex Corp. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zimek Technologies

Zimek Technologies is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision Biopsy

Precision Biopsy, LLC was formed in partnership with Allied Minds to develop and commercialize novel technology for the accurate diagnosis of prostate cancer. The company’s diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. For the first time, this unique ability will eliminate random prostate biopsies that are subject to sampling errors and can lead to inaccurate grading and staging of the disease. The scientific founders, professors Priya Werahara and John Daily of the University of Colorado, have long studied the morphology of cancer tissue. Combining their knowledge of advanced spectroscopy techniques has resulted in the ability to image the precise location of cancer in the prostate.